Biodexa Hits 100-Patient Enrollment in Phase 3 Serenta Trial; Futility Analysis Pulled Forward to Early 2027
BDRX sits 30% above its 52-week low of $0.337 on elevated volume (5.5× avg).
Summary
Biodexa announced 100 patients enrolled in its Phase 3 Serenta trial of eRapa in FAP, with the futility analysis now expected early next year and database lock around end of next year — both ahead of original expectations.
Key Events · Product Development and Regulatory · BDRX
-
100 Patients Enrolled in Phase 3 Serenta Trial
Enrollment in the registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP), branded Serenta, has reached 100 of a planned 168 patients across 29 US and European sites.
-
Futility Analysis Pulled Forward to Early 2027
Based on current PFS event accrual, the pre-specified futility analysis after 25 PFS events is now expected early next year, significantly sooner than originally anticipated.
-
Database Lock Expected Around End of 2027
Database lock after 75 PFS events is now expected around the end of next year, also ahead of the original timeline.
-
Trial Expansion Underway
Two additional clinical sites in Canada are expected to be initiated shortly, adding to the 29 active sites across the US and five European countries.
Analysis · BDRX · Life Sciences
Enrollment in the registrational Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis has reached 100 of a planned 168 patients. Management now expects the pre-specified futility analysis early next year and database lock around the end of next year — both significantly sooner than originally anticipated. This is a meaningful de-risking event for a company with a going-concern warning and only £3.23 million in cash as of June 30, 2026. Faster enrollment and earlier readouts reduce the time and capital needed to reach key value-inflection points, which matters acutely given the company's constrained balance sheet and recent reliance on warrant inducement and ATM financings. The trial is supported by a $20 million CPRIT grant, which partially offsets execution risk.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.5% of the 1750 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. The 52-week trading range was $0.34 to $44.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.